Cue Biopharma Inc (CUE) Earnings Report, Financial Results, Financial analysis

Cue Biopharma Inc narrowed first quarter of 2023 net loss per share of $-0.29 compare to net loss per share of $-0.44 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.34 realized in previous quarter.

*first quarter of 2023*
Earnings Per Share	Revenues
$ -0.29	$ 0 Mill
$+0.15	$-1M -81.3 %

Cue Biopharma Inc 's Revenue fell by -81.3 % in first quarter of 2023 (Mar 31 2023) year on year, to $0 million and advanced by 23.66 % sequentially.

Cue Biopharma Inc is Expected to report next financial results on August 03, 2023.

More on CUE's Income Statement

CUE's NET INCOME

Cue Biopharma Inc 's in thefirst quarter of 2023 recorded net loss of $-13.109 million, an improvement compare to net loss of $-14.255 million in I. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-14.592 million realized in previous quarter.

More on CUE's Growth

Cue Biopharma Inc Inventories
CUE's Cash flow In thefirst quarter of 2023 company's net cash flow was $5 million

Earnings quality

Cue Biopharma Inc does not pay out common stock dividend.

In trailing twelve-month period Cue Biopharma Inc payed $ -0.92 cash per share, on a free-cash flow basis .

Book value fell by -33.26 % sequentially to $1.23 per share, -46.92% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.23 per share from $ 1.85.

Company issued 9.07 million shares or 25.51 % in Mar 31 2023.

• More on CUE's Dividends

Market Capitalization (Millions)	175
Shares Outstanding (Millions)	45
Total Debt (Millions $)	10
Revenue (TTM) (Millions $)	0
Net Income (TTM) (Millions $)	-52
Cash Flow (TTM) (Millions $)	-12
Capital Exp. (TTM) (Millions $)	0
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	50

Earnings quality

Cue Biopharma Inc does not pay out common stock dividend.

In trailing twelve-month period Cue Biopharma Inc had negative $ -0.92 cash flow per share, on a free-cash flow basis .

Book value fell by -33.26 % sequentially to $1.23 per share, -46.92% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 1.23 per share from $ 1.85.

Company issued 9.07 million shares or 25.51 % in Mar 31 2023.

• More on CUE's Balance Sheets

Market Capitalization (Millions)	175
Shares Outstanding (Millions)	45
Total Debt (Millions $)	10
Revenue (TTM) (Millions $)	0
Net Income (TTM) (Millions $)	-52
Cash Flow (TTM) (Millions $)	-12
Capital Exp. (TTM) (Millions $)	0
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Employees (TTM) $	50

Cue Biopharma Inc

CUE's Financial Statements and Analysis